- Home
- CSTE vs NRXP Comparison
CSTE vs NRXP Comparison
Compare CSTE & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CSTE | NRXP |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.9M | 73.7M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | CSTE | NRXP |
|---|---|---|
| Price | $1.79 | $2.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $5.00 | ★ $30.50 |
| AVG Volume (30 Days) | ★ 537.7K | 446.3K |
| Earning Date | 11-12-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $400,656,000.00 | $242,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.61 | $643.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.86 | $1.15 |
| 52 Week High | $5.04 | $6.01 |
Technical Indicators
Market Signals| Indicator | CSTE | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 70.51 | 45.23 |
| Support Level | $0.86 | $2.22 |
| Resistance Level | $1.94 | $2.51 |
| Average True Range (ATR) | 0.19 | 0.19 |
| MACD | 0.10 | 0.04 |
| Stochastic Oscillator | 89.29 | 68.52 |
Price Performance
Historical ComparisonAbout CSTE Caesarstone Ltd.
Caesarstone Ltd manufactures engineered quartz surfaces. Its products include engineered quartz and porcelain slabs, which are used as kitchen countertops in renovation and remodeling, and residential construction. It also has other applications, including vanity tops, wall panels, backsplashes, floor tiles, stairs, and other interior surfaces that are used in various residential and non-residential applications. The company sells its products under the Caesarstone brand. Caesarstone's geographical segments are the United States, Canada, Latin America, Australia, Asia, Israel, and EMEA(Europe, Middle East, Africa).
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.